AIM: To investigate the bioequivalence of lansoprazole enterosoluble tablets and capsules in Chinese healthy volunteers. METHODS: Twenty volunteers were randomly divided into two groups (test and reference), with double cross over design. The concentration of lansoprazole in serum was determined by HPLC and pharmacokinetic parameters were calculated with DAS 2.0 practical pharmacokinetics program. RESULTS: The pharmacokinetic parameters of lansoprazole enterosoluble tablets and capsules were as follows: t_ 1/2 were 1.808 ± 1.031 and 1.341 ± 0.498 h, C_ max were 0.764 ± 0.385 and 0.902 ± 0.369 μg·ml~ -1 , T_ max were 3.639 ± 0.744 and 2.500 ± 1.000 h, AUC_ 0-10h were 3.024 ± 1.941 and 3.098 ± 1.742 μg·h·ml~ -1 。The relative bioavalibility of lansoprazole enterosoluble tablets was 109.57 %± 59.48 %. CONCLUSION: The statistical analysis showed that the test and reference preparation were bioequivalent.